APSR2026-1003

 
Late-Breaking
Submitted
Poster Presentation
 
AP14-016
P35
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1229720-46904-POSTER LELA_433892.pdf
Format: PDF Only
08. Lung Cancer
4

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Lela Khaibirunna A.P * Universitas Sumatera Utara Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Medan Indonesia
Noni Novisari Soeroso - Universitas Sumatera Utara Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Medan Indonesia
Desfrina Kasuma - Adam Malik Hospital Department of Pulmonology and Respiratory Medicine Medan Indonesia
Putri Chairani Eyanoer - Universitas Sumatera Utara Departemen of Primary Care and Family Medicine, Faculty of Medicine Medan Indonesia
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Lela Khaibirunna
A.P
lelakhaibirunna@gmail.com
+6281266473669
Under 30
Indonesia
Original Research
Prevalence and clinicopathological characteristics of BRAF V600E mutation in non–small cell lung cancer
Maximum 25 words
Abstract Content
Lung cancer remains a leading cause of cancer-related mortality worldwide, with more than 80% of cases classified as non–small cell lung cancer (NSCLC). Advances in precision oncology have highlighted the importance of identifying actionable molecular alterations, including BRAF V600E mutation. However, data on the prevalence and clinicopathological characteristics of BRAF V600E-mutated NSCLC in Indonesia remain limited. This study aimed to determine the prevalence and clinicopathological profile of NSCLC patients harboring BRAF V600E mutation.
A cross-sectional study was conducted among 120 patients with histopathologically confirmed NSCLC at a tertiary referral center in Indonesia. BRAF V600E mutation was detected using real-time polymerase chain reaction (RT-PCR) on formalin-fixed paraffin-embedded tissue specimens. Demographic, clinical, and histopathological data were analyzed descriptively.
Most patients were male (76.7%), aged 41–60 years (47.5%), and had a smoking history (74.2%). Adenocarcinoma was the predominant histological subtype (75%), and stage IVA was the most common clinical stage (60%). Poorly differentiated tumors accounted for 41.7% of cases. BRAF V600E mutation was identified in 4 patients (3.3%). All mutation-positive cases were male; three were smokers and one was a never-smoker. Histologically, three cases were classified as squamous cell carcinoma and one as adenocarcinoma. Tumor differentiation included one well-differentiated, one moderately differentiated, and two poorly differentiated cases.
BRAF V600E mutation was detected in 3.3% of NSCLC patients, consistent with global reports. Although uncommon, the detection of BRAF V600E mutation across different histological subtypes and differentiation grades underscores the importance of routine molecular profiling to guide personalized treatment strategies in NSCLC.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
BRAF V600E mutation, histopathological grading, non–small cell lung cancer
maximum 3 keywords and no abbreviations, separated by commas
 
255